Company CVRx, Inc.

Equities

CVRX

US1266381052

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
14.69 USD +2.08% Intraday chart for CVRx, Inc. -1.41% -53.28%

Business Summary

CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programed by a wireless clinician-controlled programmer that communicates with the IPG.

Number of employees: 200

Sales per Business

USD in Million2022Weight2023Weight Delta
Medical Device
100.0 %
22 100.0 % 39 100.0 % +74.89%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
89.4 %
18 80.2 % 35 89.4 % +94.83%
Germany
9.4 %
3 15.5 % 4 9.4 % +6.13%
Other Countries
1.3 %
1 4.3 % 0 1.3 % -49.12%

Managers

Managers TitleAgeSince
Chief Executive Officer 58 22-12-20
Director of Finance/CFO 41 15-07-31
Chief Operating Officer - 06-06-30
Chief Tech/Sci/R&D Officer 57 16-08-31
Sales & Marketing 61 20-12-31
General Counsel 52 22-02-28
Sales & Marketing 47 12-09-30
Corporate Secretary 71 03-09-30

Members of the board

Members of the board TitleAgeSince
Director/Board Member 59 08-09-30
Director/Board Member 50 20-06-30
Director/Board Member 55 20-06-30
Director/Board Member 47 13-06-30
Director/Board Member 68 21-07-11
Chief Executive Officer 58 22-12-20

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 21,595,464 18,165,627 ( 84.12 %) 0 84.12 %

Shareholders

NameEquities%Valuation
Johnson & Johnson Innovation - JJDC, Inc.
19.61 %
4,103,430 19.61 % 75 M $
NEA Management Co. LLC
11.33 %
2,370,542 11.33 % 43 M $
Vensana Capital Management LLC
8.177 %
1,711,355 8.177 % 31 M $
Gilde Healthcare Partners BV
6.526 %
1,365,743 6.526 % 25 M $
Action Potential Venture Capital
4.815 %
1,007,583 4.815 % 18 M $
Treo Ventures LLC
4.460 %
933,383 4.460 % 17 M $
Lord, Abbett & Co. LLC
3.702 %
774,670 3.702 % 14 M $
BlackRock Advisors LLC
3.695 %
773,363 3.695 % 14 M $
Vanguard Fiduciary Trust Co.
2.688 %
562,592 2.688 % 10 M $
Balyasny Asset Management LP
1.945 %
407,008 1.945 % 7 M $

Company contact information

CVRx, Inc.

9201 West Broadway Avenue Suite 650

55445, Minneapolis

+

http://www.cvrx.com
address CVRx, Inc.(CVRX)